<DOC>
	<DOCNO>NCT01488526</DOCNO>
	<brief_summary>Immunoprophylaxis failure hepatitis B virus ( HBV ) lead vertical transmission remain concern report approximately 8-15 % infant bear hepatitis B e antigen ( HBeAg ) positive mother high level HBV DNA . Maternal HBV DNA &gt; 6log10 copies/mL ( &gt; 200,000 IU/mL ) major risk mother-to-child transmission . Prior observational study show antiviral therapy include lamivudine telbivudine use late pregnancy safely reduce rate vertical transmission special population compare untreated patient . Tenofovir Disoproxil ( TDF ) , pregnancy category B medication , reduce HBV DNA normalize serum alanine aminotransferase ( ALT ) chronic hepatitis B patient ( CHB ) adverse effect . Two aspect tenofovir use pregnancy evaluate prospectively study : 1 . The data tolerability safety HBeAg+ pregnant woman HBV DNA &gt; 6log10 copies/mL ( &gt; 200,000 IU/mL ) late pregnancy infant . 2 . Its efficacy reduction HBV vertical transmission rate .</brief_summary>
	<brief_title>Tenofovir Late Pregnancy Prevent Vertical Transmission Hepatitis B Virus</brief_title>
	<detailed_description>Eligible mother randomize ( 1:1 ) either TDF-treated group untreated group 100 subject arm . The treatment group receive TDF start week 30-32 gestation week 4 postpartum ; follow continue post-partum week 28 infant age 28 week . Untreated group receive standard care similar follow-up schedule treatment group .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>document CHB infection HBsAg positive &gt; 6 month HBeAg+ CHB pregnant woman gestational age 3032 week HBV DNA &gt; 6 log10 copies/mL ( &gt; 200,000 IU/mL ) mother father child willing consent study Major coinfection hepatitis A , C , D , E , HIV1 sexually transmit disease ( STD ) decompensated liver disease significant comorbidity history abortion , diagnosis fetal defect , congenital malformation prior pregnancy antiviral use within six month prior pregnancy , history renal tubular function impairment due adefovir . requirement medication pregnancy manage chronic disease ( ) concurrent treatment immunemodulators , cytotoxic drug , steroid biological father child CHB clinical sign threaten miscarriage early pregnancy evidence hepatocellular carcinoma maternal alanine aminotransferase ( ALT ) &gt; = 5 x upper limit normal ( U/mL ) , Total Bilirubin &gt; = 2 , glomerular filtration rate ( GFR ) &lt; 100 , Albumin &lt; 25 g/L evidence fetal deformity ultrasound examination patient participate clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Vertical transmission</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Antiviral treatment</keyword>
</DOC>